NRx Pharmaceuticals, Inc. (NRXPW)

US — Healthcare Sector
Peers: AGNPF  RLFTY  NRXP  RLF.SW  QSIAW  RVPHW 

Automate Your Wheel Strategy on NRXPW

With Tiblio's Option Bot, you can configure your own wheel strategy including NRXPW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NRXPW
  • Rev/Share 0.0002
  • Book/Share -1.9859
  • PB -1.274
  • Debt/Equity -0.2873
  • CurrentRatio 0.1135
  • ROIC 0.5134

 

  • MktCap 49343602.0
  • FreeCF/Share -0.6642
  • PFCF -4.1423
  • PE -1.3427
  • Debt/Assets 2.1149
  • DivYield 0
  • ROE 1.3147

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About NRx Pharmaceuticals, Inc. (NRXPW)

  • IPO Date 2017-12-01
  • Website https://www.nrxpharma.com
  • Industry Biotechnology
  • CEO Jonathan C. Javitt
  • Employees None

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.